Scarica l'app Stockscreener
1.19
5.31%
0.06
Dopo l'orario di chiusura:
1.18
-0.01
-0.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.13
Aprire:
$1.11
Volume 24 ore:
2.03M
Relative Volume:
2.26
Capitalizzazione di mercato:
$36.74M
Reddito:
$680.00K
Utile/perdita netta:
$-75.33M
Rapporto P/E:
-0.1923
EPS:
-6.1898
Flusso di cassa netto:
$-57.38M
1 W Prestazione:
+31.97%
1M Prestazione:
+15.53%
6M Prestazione:
-24.68%
1 anno Prestazione:
-74.95%
Intervallo 1D:
$1.015
$1.24
Intervallo di 1 settimana:
$0.893
$1.24
Portata 52W:
$0.7365
$6.85
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.19 | 32.73M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Rodman & Renshaw | Buy |
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan
Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo! Finance Canada
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics (BTAI) Earnings Date and Reports 2026 $BTAI - marketbeat.com
BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget
BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor - TradingView
BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline - Stock Titan
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Q2'26 Earnings: EPS estimate is (0.44) USD - TradingView
BioXcel Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
BioXcel Therapeutics (BTAI) Tests Key Support at $0.84 as Biotech Selloff ContinuesAnchored VWAP - dars.gov.et
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Q2'26 Earnings: revenue estimate is 484.63K USD - TradingView
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal - TradingView
BTAI|BioXcel Therapeutics Inc|Price:0.830|Chg%:-0.011 - TradingKey
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BTAI|BioXcel Therapeutics Inc|Price:1.180|Chg%:+0.050 - TradingKey
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioXcel Therapeutics Market Sentiment - Benzinga España
BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022 - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20 - TradingView
BioXcel Therapeutics Inc (BTAI) Balance Sheet - TradingKey
TradingKey - TradingKey
BTAI Q1 2026 Earnings: Narrower Loss Surprises, But Revenue Remains AbsentEPS Consistency Score - dars.gov.et
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows Despite Missing Revenue MilestoneGuidance vs Actual - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et
BioXcel Therapeutics (BTAI) Investor update Summary - Quartr
BioXcel Therapeutics (BTAI) Q1 2026 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Registration Filing Summary - Quartr
BioXcel Therapeutics (BTAI) Q2 2024 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
BioXcel Therapeutics (BTAI) Q4 2025 earnings summary - Quartr
BTAI Q1 2026 Earnings: Narrowing Losses as EPS Surpasses Estimates Amid Pipeline ProgressROE Trend Analysis - Bölüm Sonu Canavarı
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment - Stock Titan
BioXcel Therapeutics (BTAI) Holds Above $1.31 Support Amid Modest UptickFundamentals - dars.gov.et
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):